Ertapenem Sodium
Tier C — Watch / tradeErtapenem Sodium
Targets：PBPs
Brand：Invanz
Indications (approved)：Complicated skin and skin structure infection, Intra-abdominal infection, Bacteraemia, Urinary tract infection, Community-acquired pneumonia, Pyelonephritis, Bacterial infection, Gram-negative bacterial infection
Regional status
Synthetic routes & intermediates4 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| ERTA-001 | 121-92-6 | 3-nitrobenzoic acid |
| ERTA-002 | 106-95-6Available | 3-bromoprop-1-ene |
| ERTA-003 | 779-80-6 | allyl 3-nitrobenzoate |
| ERTA-004 | 56768-05-9 | allyl 3-aminobenzoate |
| ERTA-005 | 145352-54-1 | (2S,4S)-4-(acetylthio)-1-((allyloxy)carbonyl)pyrrolidine-2-carboxylic acid |
| ERTA-006 | 153774-27-7 | allyl (2S,4S)-4-(acetylthio)-2-((3-((allyloxy)carbonyl)phenyl)carbamoyl)pyrrolidine-1-carboxylate |
| ERTA-007 | 1355671-99-6 | allyl (2S,4S)-2-((3-((allyloxy)carbonyl)phenyl)carbamoyl)-4-mercaptopyrrolidine-1-carboxylate |
| ERTA-008 | 133808-94-3 | allyl (4R,5R,6S)-3-((diphenoxyphosphoryl)oxy)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate |
| ERTA-009 | 153774-28-8 | allyl (4R,5S,6S)-3-(((3S,5S)-1-((allyloxy)carbonyl)-5-((3-((allyloxy)carbonyl)phenyl)carbamoyl)pyrrolidin-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate |
| ERTA-010 | 2033-24-1 | 2,2-dimethyl-1,3-dioxane-4,6-dione |
| ERTA-011 | 107560-22-5 | allyl (R)-2-diazo-4-((2R,3S)-3-((R)-1-hydroxyethyl)-4-oxoazetidin-2-yl)-3-oxopentanoate |
| ERTA-012 | 117893-97-7 | allyl (4R,5R,6S)-6-((R)-1-hydroxyethyl)-4-methyl-3,7-dioxo-1-azabicyclo[3.2.0]heptane-2-carboxylate |
| ERTA-013 | 2524-64-3 | diphenyl phosphorochloridate |
| Code | CAS No. | Intermediate |
|---|---|---|
| ERTA-014 | 90822-24-5 | (R)-2-diazo-4-((2R,3S)-3-((R)-1-hydroxyethyl)-4-oxoazetidin-2-yl)-3-oxopentanoic 4-nitrobenzoic anhydride |
| ERTA-015 | 104873-15-6 | (4R,5R,6S)-6-((R)-1-hydroxyethyl)-4-methyl-3,7-dioxo-1-azabicyclo[3.2.0]heptane-2-carboxylic 4-nitrobenzoic anhydride |
| ERTA-016 | 14254-41-2 | bis(2,4-dichlorophenyl) phosphorochloridate |
| ERTA-017 | 1349768-81-5 | (4R,5R,6S)-3-((bis(2,4-dichlorophenoxy)phosphoryl)oxy)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic 4-nitrobenzoic anhydride |
| ERTA-018 | 202467-69-4 | 3-((2S,4S)-4-mercapto-1-(((4-nitrobenzyl)oxy)carbonyl)pyrrolidine-2-carboxamido)benzoic acid |
| ERTA-019 | 202467-70-7 | 3-((2S,4S)-4-(((4R,5S,6S)-6-((R)-1-hydroxyethyl)-4-methyl-2-(((4-nitrobenzyl)oxy)carbonyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl)thio)-1-(((4-nitrobenzyl)oxy)carbonyl)pyrrolidine-2-carboxamido)benzoic acid |
| Code | CAS No. | Intermediate |
|---|---|---|
| ERTA-020 | 90776-59-3 | 4-nitrobenzyl (4R,5R,6S)-3-((diphenoxyphosphoryl)oxy)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate |
| ERTA-021 | 219909-83-8 | 3-((2S,4S)-4-mercaptopyrrolidine-2-carboxamido)benzoic acid hydrochloride |
| ERTA-022 | 866186-69-8 | 1,1,3,3-tetramethylguanidine 3-((2S,4S)-4-(((4R,5S,6S)-6-((R)-1-hydroxyethyl)-4-methyl-2-(((4-nitrobenzyl)oxy)carbonyl)-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl)thio)pyrrolidine-2-carboxamido)benzoate |
| Code | CAS No. | Intermediate |
|---|---|---|
| ERTA-023 | - | (2S,4R)-1-(diisopropoxyphosphoryl)-4-hydroxypyrrolidine-2-carboxylic acid |
| ERTA-024 | - | (2S,4R)-1-(diisopropoxyphosphoryl)-4-hydroxypyrrolidine-2-carboxylic diphenylphosphinic anhydride |
| ERTA-025 | - | (2S,4R)-1-(diisopropoxyphosphoryl)-4-((methylsulfonyl)oxy)pyrrolidine-2-carboxylic diphenylphosphinic anhydride |
| ERTA-026 | - | diisopropyl ((1S,4S)-3-oxo-2-thia-5-azabicyclo[2.2.1]heptan-5-yl)phosphonate |
| ERTA-027 | 99-05-8 | 3-aminobenzoic acid |
| ERTA-028 | - | 3-((2S,4S)-1-(diisopropoxyphosphoryl)-4-mercaptopyrrolidine-2-carboxamido)benzoic acid |
| ERTA-029 | 219909-83-8 | 3-((2S,4S)-4-mercaptopyrrolidine-2-carboxamido)benzoic acid hydrochloride |
Frequently asked questions
What are the approved indications of Ertapenem Sodium?
Approved indications include: Complicated skin and skin structure infection, Intra-abdominal infection, Bacteraemia, Urinary tract infection, Community-acquired pneumonia, Pyelonephritis, Bacterial infection, Gram-negative bacterial infection.
When does the Ertapenem Sodium patent expire?
No public expiry year is available for Ertapenem Sodium yet; this page updates once verified.
How many synthesis routes are recorded for Ertapenem Sodium?
4 synthesis routes are recorded; the shortest is 2 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Ertapenem Sodium intermediates?
1 intermediate CAS of Ertapenem Sodium are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Ertapenem Sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29